Adversarial Injection · Obinutuzumab (Gazyva; GA101; CAS 949142-67-0; MW ~146,100 Da; IgG1 kappa humanized glycoengineered GlycoMab anti-CD20 type II monoclonal antibody [FIFTY-NINTH MECHANISM CLASS in Glyphward 632-attack portfolio — FIRST TYPE II CD20 ANTIBODY EVER FDA APPROVED (BLA 125486 November 1 2013): CD20 (MS4A1; MEMBRANE-SPANNING 4-DOMAINS SUBFAMILY A MEMBER 1) was the first antigen ever successfully targeted by a monoclonal antibody in oncology (rituximab 1997; Rituxan BLA 103705); obinutuzumab is the second distinct CD20-targeting antibody class (type II) ever FDA approved, arriving 16 years after type I rituximab; the type I / type II CD20 antibody classification was proposed by Cragg et al. (2003) based on distinct Fc-dependent and Fc-independent killing mechanisms; TYPE I vs TYPE II CD20 ANTIBODY MECHANISM: type I antibodies (rituximab, ofatumumab) engage CD20 with the antibody binding in the 'standing' orientation relative to the cell surface — CD20 is redistributed INTO lipid rafts (membrane microdomains rich in cholesterol and sphingolipids → favorable for C1q binding and CDC activation) → enhanced complement-dependent cytotoxicity (CDC) but standard ADCC; type II antibodies (obinutuzumab) engage CD20 with a distinct ~90° elbow-hinge rotation — CD20 is NOT translocated into lipid rafts → reduced CDC vs type I because C1q binding is less favorable outside lipid rafts; HOWEVER, type II engagement activates an additional direct cell death pathway via: (a) homotypic adhesion (CD20-cross-linked B cells aggregate) and (b) lysosomal-mediated direct cell death (non-apoptotic; caspase-independent; actin cytoskeleton reorganization → lysosomal membrane permeabilization → cathepsin release → cell death) — this lysosomal pathway is absent from type I antibodies; GLYCOMAB GLYCOENGINEERING (GLYCART BIOTECHNOLOGY / ROCHE): obinutuzumab is produced using GlycoMab technology (developed at Glycart Biotechnology AG, Schlieren Switzerland; acquired by Roche AG 2005 for ~CHF 235M); GlycoMab involves stable overexpression of N-acetylglucosaminyltransferase III (GnTIII; EC 2.4.1.144; the enzyme that adds bisecting N-acetylglucosamine [GlcNAc] to the β-mannose core of N-glycans) AND Golgi α-mannosidase II (ManII) in the CHO production cell line; GnTIII overexpression adds a bisecting GlcNAc to the biantennary complex N-glycan at Asn-297 (N297) in the Fc CH2 domain; the bisecting GlcNAc sterically clashes with the FUT8 enzyme (α-1,6-fucosyltransferase) and reduces subsequent core fucosylation → the N297 glycan is both bisected AND afucosylated; bisected + afucosylated N297 glycan has dramatically enhanced affinity for FcγRIIIa (CD16a) on NK cells (~10-50× enhanced binding; Umana et al. Nature Biotechnology 1999; the foundational GlycoMab paper); GLYCOMAB vs POTELLIGENT: POTELLIGENT (Kyowa Kirin; mogamulizumab [attack #631]) uses FUT8 knockout to eliminate fucosylation without adding bisecting GlcNAc; GlycoMab (Roche) adds bisecting GlcNAc + incidentally reduces fucosylation via GnTIII overexpression — these are DISTINCT glycoengineering approaches both producing enhanced ADCC; obinutuzumab (GlycoMab) was the first ROCHE-produced glycoengineered antibody approved in the US; OBINUTUZUMAB INDICATIONS (BLA 125486): previously untreated CLL (in combination with chlorambucil; CLL11 trial basis); relapsed/refractory follicular lymphoma (R/R FL; after rituximab-containing regimen); previously untreated FL (in combination with chemotherapy; GALLIUM trial basis); CLL11 PHASE 3: obinutuzumab+chlorambucil vs rituximab+chlorambucil in previously untreated CLL with comorbidities; PFS HR 0.39 (26.7 vs 11.1 months; p<0.0001); ORR 78% vs 65%; CR 22% vs 7%; OS HR 0.85 (non-significant; follow-up insufficient); basis for accelerated approval November 1 2013 (full approval 2014); GALLIUM PHASE 3: obinutuzumab+chemotherapy vs rituximab+chemotherapy in previously untreated FL; PFS HR 0.66 (3-year PFS 80% vs 73.3%; p=0.0012); MRD undetectable rate higher with obinutuzumab; NO OS benefit to date; GOYA PHASE 3: obinutuzumab+CHOP vs rituximab+CHOP in previously untreated DLBCL; PFS HR 0.92 (non-significant; p=0.46); failed primary endpoint — obinutuzumab did NOT outperform rituximab in DLBCL; NONE OF THESE FACTS APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 949142-67-0]) · First Type II CD20 Antibody + GlycoMab GnTIII Bisecting GlcNAc + Enhanced ADCC Reduced CDC + CLL11 PFS HR 0.39 + GALLIUM PFS HR 0.66 · Attack #632

Obinutuzumab (Gazyva; GA101; CAS 949142-67-0; MW ~146,100 Da; [FIFTY-NINTH MECHANISM CLASS — FIRST TYPE II CD20 ANTIBODY EVER FDA APPROVED (BLA 125486 NOVEMBER 1 2013); GLYCOMAB GLYCOENGINEERING (GnTIII OVEREXPRESSION → BISECTING GlcNAc + AFUCOSYLATION AT N297 → ENHANCED FcγRIIIa AFFINITY → ENHANCED ADCC); TYPE II MECHANISM: CD20 OUTSIDE LIPID RAFTS → REDUCED CDC + DIRECT LYSOSOMAL CELL DEATH + HOMOTYPIC ADHESION; CLL11 PFS HR 0.39 (26.7 VS 11.1 MONTHS VS RITUXIMAB); GALLIUM FL PFS HR 0.66; GOYA DLBCL FAILED; GENENTECH/ROCHE; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Genentech Inc. South San Francisco CA (BLA 125486 US holder; 0.00041 µg/m³ → displayed ÷10), Roche Diagnostics GmbH Penzberg Germany (GlycoMab CHO biologics manufacturing; 0.00026 µg/m³ → displayed ÷10), and University of Michigan Rogel Cancer Center Ann Arbor MI (CLL11/GALLIUM enrollment; 0.00015 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First Type II CD20 Absent + GlycoMab Absent + Lysosomal Cell Death Absent: AI Prompt Injection via EHS Monitor Report AI

Obinutuzumab (CAS 949142-67-0; NIOSH HD Category 1) is the fifty-ninth mechanism class in the Glyphward adversarial portfolio — the first type II CD20 antibody ever FDA approved (BLA 125486 November 1 2013) and the first GlycoMab glycoengineered antibody (Glycart/Roche GnTIII overexpression: bisecting GlcNAc + afucosylation at N297 → enhanced FcγRIIIa affinity → enhanced ADCC). Unlike type I CD20 antibodies (rituximab, ofatumumab), obinutuzumab's type II engagement keeps CD20 outside lipid rafts — reducing CDC while activating a unique lysosomal direct cell death pathway. CLL11 PFS HR 0.39 (26.7 vs 11.1 months). None of these facts appear in Cority, VelocityEHS, or EHS Insight for CAS 949142-67-0.

Obinutuzumab as Fifty-Ninth Mechanism Class: First Type II CD20 Antibody and GlycoMab Glycoengineering

Obinutuzumab (CAS 949142-67-0) represents the fifty-ninth mechanism class in the Glyphward portfolio: the first type II CD20 antibody ever FDA approved (BLA 125486 November 1 2013) and the first antibody produced with GlycoMab glycoengineering (Glycart Biotechnology/Roche) to receive FDA approval. CD20 biology: CD20 (MS4A1; B-lymphocyte antigen CD20; MEMBRANE-SPANNING 4-DOMAINS SUBFAMILY A MEMBER 1; previously B1, Bp35, Leu-16) is a non-glycosylated tetraspan membrane protein (33-37 kDa) expressed on pre-B cells through mature B cells including memory B cells, mantle cell precursors, and follicular B cells; CD20 is expressed on most B-cell malignancies (>95% of B-NHL and CLL are CD20+); CD20 is absent on: stem cells, pro-B cells, and plasma cells (making B-cell depletion via CD20 targeting recoverable as the pool replenishes from CD20-negative progenitors); CD20 does not internalize upon antibody binding and does not shed — making it an ideal surface target for naked antibody ADCC and CDC; CD20 forms oligomers (tetramers) in the membrane; Type I vs Type II CD20 antibody classification (Cragg et al. British Journal of Haematology 2004): type I antibodies (rituximab [chimeric IgG1; BLA 103705 1997]; ofatumumab [fully human IgG1; BLA 125326 2009]; ublituximab [glycoengineered type I]) engage the large extracellular loop of CD20 in a 'standing' orientation causing CD20 redistribution INTO lipid rafts (cholesterol-rich membrane microdomains) → favorable C1q binding → strong CDC activation → type I antibodies are potent CDC mediators but depend on complement availability; type II antibodies (obinutuzumab [humanized IgG1 GlycoMab]) engage CD20 with a ~90° elbow-hinge rotation change at the Fc-Fab elbow — this altered geometry causes CD20 to remain OUTSIDE lipid rafts → reduced C1q access → reduced CDC relative to type I; however, the type II orientation activates additional Fc-independent direct cell death pathways: (a) homotypic adhesion — cross-linked CD20 outside lipid rafts triggers B-cell aggregation via actin cytoskeleton reorganization; (b) direct cell death via lysosomal pathway — CD20 cross-linking outside lipid rafts signals through actin rearrangement → lysosomal membrane permeabilization (LMP) → cathepsin B/D/L release into cytoplasm → non-apoptotic, caspase-independent cell death; this lysosomal direct cell death mechanism is absent from type I rituximab at comparable concentrations; GlycoMab glycoengineering (Glycart Biotechnology AG, Schlieren Switzerland; founded 1999 by Pablo Umana and colleagues from ETH Zürich; acquired by Roche AG November 2005): stable overexpression of N-acetylglucosaminyltransferase III (GnTIII; encoded by MGAT3 gene; EC 2.4.1.144 — the enzyme that transfers a GlcNAc residue in β1,4 linkage to the β-mannose of the biantennary N-glycan core, creating a 'bisected' glycan) in CHO production cells for obinutuzumab; GnTIII overexpression adds bisecting GlcNAc to the N297 Fc N-glycan; bisecting GlcNAc competes with and inhibits subsequent FUT8 (α-1,6-fucosyltransferase) activity in the Golgi → N297 glycan is both bisected AND shows reduced core fucosylation (not complete abolition as in FUT8 knockout, but substantially reduced; obinutuzumab Fc N297 glycan: ~30-50% afucosylated bisected species, vs <10% afucosylated in rituximab); the resulting bisected + afucosylated N297 glycan has enhanced FcγRIIIa (CD16a) binding affinity (~10-50× vs rituximab fucosylated IgG1 Fc; Umana et al. Nature Biotechnology 1999; seminal glycoengineering paper) → significantly enhanced ADCC (NK cell killing at lower antibody concentrations and higher efficiency per NK cell); GlycoMab enhanced ADCC combined with type II direct cell death gives obinutuzumab a dual mechanism advantage: enhanced Fc-dependent NK killing + Fc-independent lysosomal tumor cell death; CLL11 Phase 3 (ClinicalTrials.gov NCT01010061; Goede et al. NEJM 2014): obinutuzumab+chlorambucil (G-Clb) vs rituximab+chlorambucil (R-Clb) in previously untreated CLL patients with comorbidities (Cumulative Illness Rating Scale [CIRS] >6 or creatinine clearance <70 mL/min); n=781; PFS HR 0.39 (26.7 vs 11.1 months vs R-Clb; p<0.0001); ORR 78% vs 65%; CR/CRi 20.7% vs 7%; minimal residual disease (MRD) undetectable 19.5% vs 2.6%; OS HR 0.85 (not significant; insufficient follow-up); basis for accelerated BLA 125486 approval November 1 2013; GALLIUM Phase 3 (NCT01332968; Marcus et al. NEJM 2017): obinutuzumab+chemotherapy (G-chemo: G-CHOP, G-CVP, or G-bendamustine) vs rituximab+chemotherapy (R-chemo) in previously untreated FL; n=1202; PFS HR 0.66 (80% vs 73.3% at 2 years; p=0.0012); MRD-neg rate higher with G-chemo; OS HR 0.94 (non-significant; no OS benefit to date); GOYA Phase 3 (NCT01287741): obinutuzumab+CHOP vs rituximab+CHOP in previously untreated DLBCL; n=1418; PFS HR 0.92 (p=0.46; non-significant); failed primary endpoint — obinutuzumab did NOT improve on rituximab in DLBCL; NONE OF THESE MECHANISMS OR TRIAL DATA — type II mechanism, GlycoMab, GnTIII bisecting GlcNAc, afucosylation, direct lysosomal death, reduced CDC, CLL11 PFS HR 0.39, GALLIUM PFS HR 0.66, GOYA failure — appear in Cority, VelocityEHS, or EHS Insight for CAS 949142-67-0.

Surface 1 — Genentech Inc. South San Francisco CA BLA 125486 US Holder Gazyva AI

At Genentech Inc. South San Francisco CA (1 DNA Way, South San Francisco CA 94080; San Mateo County CA; GENENTECH GAZYVA CONTEXT: Genentech Inc. (wholly owned US subsidiary of Roche AG Basel Switzerland) holds BLA 125486 for Gazyva (obinutuzumab) 1,000 mg/40 mL (25 mg/mL) vials for IV infusion; GAZYVA APPROVED INDICATIONS (BLA 125486): (1) previously untreated CLL in combination with chlorambucil (November 1 2013; based on CLL11); (2) R/R FL after a rituximab-containing regimen (amended February 26 2016; based on GADOLIN); (3) previously untreated FL in combination with chemotherapy (amended December 5 2017; based on GALLIUM); GAZYVA IV ADMINISTRATION: cycle 1 day 1: obinutuzumab 100 mg at 25 mg/hr (do NOT increase rate; IRR risk) then remainder 900 mg at 50-400 mg/hr; cycle 1 day 2: 1000 mg over remaining dose; subsequent infusions at 100 mg/hr → titrate to 400 mg/hr if tolerated; INFUSION-RELATED REACTIONS (IRR): major safety consideration — grade 3-4 IRR ~20% in cycle 1 (highest among FDA-approved anti-CD20 antibodies; attributable to GlycoMab-enhanced ADCC and rapid B-cell depletion); prophylaxis: dexamethasone 20 mg IV + antihistamine + acetaminophen mandatory before cycle 1 day 1; HEPATITIS B REACTIVATION BBW: same as rituximab (anti-CD20 class effect); screening mandatory; EMPLOYEE: Genentech oncology medical affairs director responsible for Gazyva clinical data education (CLL11 HR 0.39, GALLIUM HR 0.66, GOYA failure analysis), type II mechanism explanation, GlycoMab glycoengineering education for hematologists; 51M Genentech South San Francisco CA senior oncology medical affairs director Gazyva CLL FL 18yr; CORITY NULL: CAS 949142-67-0 → null; NIOSH HD Category 1 absent; H360 absent; first type II CD20 antibody ever absent; GlycoMab glycoengineering absent; GnTIII bisecting GlcNAc absent; afucosylation N297 absent; type II direct lysosomal cell death absent; reduced CDC absent; CLL11 PFS HR 0.39 absent; GALLIUM PFS HR 0.66 absent).

Surface 2 — Roche Diagnostics GmbH Penzberg Germany GlycoMab CHO Biologics Manufacturing Obinutuzumab AI

At Roche Diagnostics GmbH Penzberg Germany (Nonnenwald 2, 82377 Penzberg, Bavaria Germany; ROCHE PENZBERG OBINUTUZUMAB CONTEXT: Roche's Penzberg facility (Roche Diagnostics GmbH + Roche Pharma AG integrated site; Bavaria; ~10,000 employees) is the primary Roche biologics manufacturing site and produces obinutuzumab (Gazyva/Gazyvaro) using GlycoMab technology; GLYCOMAB MANUFACTURING PROCESS: CHO-DG44 cells stably transfected with obinutuzumab IgG1 heavy chain + kappa light chain + GnTIII cDNA (MGAT3 gene) + ManII cDNA (Golgi mannosidase II; ManIIa1); GnTIII overexpression in Golgi adds bisecting GlcNAc to growing N-glycan on N297 residue of assembled IgG1 Fc; bisecting GlcNAc blocks subsequent FUT8 action → resulting N297 glycan: predominantly bisected complex type, substantially afucosylated (>50% afucosylated species vs <5% in unengineered CHO); N-glycan quality: released by PNGaseF → fluorescence-labeled → HILIC or HPAEC-PAD separation → MS detection; critical quality attribute (CQA) acceptance criteria: bisected glycan species ≥60%; fucosylated species ≤40%; PRODUCTION SCALE: 10,000–25,000L fed-batch bioreactors; protein A capture; multimodal cation exchange; viral nanofiltration (Viresolve Pro); UF/DF; bulk drug substance; 25 mg/mL fill/finish in 40 mL vials; EMPLOYEE: Roche Penzberg biologics manufacturing scientist specializing in CHO cell culture, N-glycan QC release testing (HILIC-UPLC-MS), and GlycoMab CQA monitoring for obinutuzumab batches; 46F Roche Penzberg Germany biologics manufacturing scientist obinutuzumab GlycoMab 15yr; VELOCITYEHS NULL: CAS 949142-67-0 → null; NIOSH HD Category 1 absent; H360 absent; first type II CD20 antibody absent; GlycoMab technology absent; GnTIII overexpression CHO absent; bisecting GlcNAc N297 CQA absent; afucosylation absent; type II CD20 mechanism absent).

Surface 3 — University of Michigan Rogel Cancer Center Ann Arbor MI CLL11 GALLIUM Enrollment Hematology-Oncology Pharmacist AI

At University of Michigan Rogel Cancer Center Ann Arbor MI (1500 E. Medical Center Drive, Ann Arbor MI 48109; Washtenaw County MI; UNIVERSITY OF MICHIGAN GAZYVA CONTEXT: University of Michigan Rogel Cancer Center (UMRCC) is a National Cancer Institute (NCI)-designated comprehensive cancer center and enrolled patients in the CLL11 and GALLIUM Phase 3 obinutuzumab trials; UMRCC hematology-oncology pharmacist prepares obinutuzumab for CLL and FL patients: Gazyva 1,000 mg/40 mL vials; diluted in 250 mL NS for cycle 1 day 1 split-dose infusion (100 mg Day 1 + 900 mg Day 2) and 1,000 mg NS infusion for subsequent cycles; INFUSION REACTION MANAGEMENT PROTOCOL: mandatory premedication cycle 1 day 1: dexamethasone 20 mg IV + diphenhydramine 25 mg IV + acetaminophen 650 mg PO 30-60 min prior; rate titration slow protocol (25→50→100→150 mg/hr at 30-min intervals only if no reaction); emergency protocol for Grade 3-4 IRR: immediate stop, diphenhydramine IV, epinephrine available, corticosteroids; B-CELL DEPLETION MONITORING: obinutuzumab causes deep B-cell depletion (CD19+ B cells often undetectable by cycle 2); monitoring: CBC with differential, flow cytometry for B-cell reconstitution (typically 6-9 months post-treatment before B cells recover); HYPOGAMMAGLOBULINEMIA: obinutuzumab causes IgG suppression (B-cell depletion effect); monitor IgG levels; IVIG supplementation if IgG <400 mg/dL with infection; EHS INSIGHT NULL: CAS 949142-67-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first type II CD20 antibody absent; GlycoMab absent; type II lysosomal death absent; reduced CDC absent; CLL11 PFS HR 0.39 absent; GALLIUM FL PFS HR 0.66 absent; H360 absent; NIOSH HD Cat 1 absent; 42M University of Michigan Rogel Cancer Center Ann Arbor MI hematology-oncology pharmacist obinutuzumab CLL/FL 13yr).

Integrating Glyphward into Obinutuzumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every obinutuzumab CAS 949142-67-0 monitoring data ingestion point — before Cority at Genentech Inc. South San Francisco CA, before VelocityEHS at Roche Penzberg Germany, and before EHS Insight at University of Michigan Rogel Cancer Center Ann Arbor MI. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; FIFTY-NINTH MECHANISM CLASS — FIRST TYPE II CD20 ANTIBODY EVER FDA APPROVED (BLA 125486 November 1 2013; distinct from type I rituximab, ofatumumab; type II CD20 = CD20 outside lipid rafts → reduced CDC vs type I + direct lysosomal cell death + homotypic adhesion) + GLYCOMAB GLYCOENGINEERING (Glycart/Roche GnTIII overexpression CHO → bisecting GlcNAc at N297 + incidental afucosylation → enhanced FcγRIIIa affinity → enhanced ADCC; distinct from POTELLIGENT FUT8 knockout [mogamulizumab attack #631]) + CLL11 PFS HR 0.39 (26.7 vs 11.1 months vs rituximab-Clb; first-line CLL) + GALLIUM FL PFS HR 0.66 [5 pts]; Genentech South San Francisco CA + Roche Penzberg Germany + University of Michigan Rogel Cancer Center Ann Arbor MI [3 pts]; first type II CD20 absent; GlycoMab absent; lysosomal death absent; CLL11 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_obinutuzumab(cas: str, reading_ugm3: float) -> dict:
    """Scan obinutuzumab with fifty-ninth-class first-type-ii-cd20-antibody glycomab context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fifty_ninth_class_first_type_ii_cd20_antibody_ever_glycomab_gntiii_bisecting_glcnac_afucosylation_n297_enhanced_adcc_reduced_cdc_lysosomal_direct_death_cll11_pfs_hr_0_39_gallium_fl_pfs_hr_0_66_genentech_roche_bla_125486"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fifty_ninth_class,
    #                    first_type_ii_cd20_antibody_ever, glycomab_gntiii,
    #                    bisecting_glcnac_n297, lysosomal_direct_death,
    #                    cll11_pfs_hr_0_39, h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_obinutuzumab("949142-67-0", 0.00041))
    print(r)
    # {'hd_category': 1, 'fifty_ninth_class': True,
    #  'first_type_ii_cd20_antibody_ever': True,
    #  'glycomab_gntiii': True,
    #  'bisecting_glcnac_n297': True,
    #  'lysosomal_direct_death': True,
    #  'cll11_pfs_hr_0_39': True,
    #  'h360_absent': True}